Literature DB >> 7536478

Lineage-unrestricted hematologic response to granulocyte colony-stimulating factor in a patient with refractory anemia with excess blasts.

N Yokose1, K Ogata, E An, H Tamura, K Kamikubo, K Dan, T Nomura.   

Abstract

We report a patient with refractory anemia with excess blasts who showed a lineage-unrestricted hematologic response to granulocyte colony-stimulating factor (G-CSF). After 17 months of a stable disease state, the patient developed pneumonia, progression of cytopenia, and reduced cellularity and blast mass in the bone marrow. He was given G-CSF to overcome the pneumonia. Not only the neutrophil count, but also the platelet count increased soon after initiation of the G-CSF therapy; both counts became normal on the fifth day of the G-CSF therapy. Additionally, the anemia improved gradually. The neutrophil and platelet counts were maintained in the normal range for 3 months after cessation of the G-CSF. In vitro studies showed that G-CSF alone stimulated megakaryocyte colony formation from bone marrow mononuclear cells (BMMNC), and accessory cells in the BMMNC were necessary for expression of this G-CSF-induced in vitro megakaryocytopoiesis. These results suggest that, in coordination with accessory cells, G-CSF stimulated megakaryocytopoiesis in the patient. This case provides valuable information for understanding the mechanisms of a lineage-unrestricted hematologic response to G-CSF, which is very rarely observed in MDS.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7536478     DOI: 10.1007/bf01682038

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  21 in total

1.  Haemopoietic colony stimulating factors promote cell survival by suppressing apoptosis.

Authors:  G T Williams; C A Smith; E Spooncer; T M Dexter; D R Taylor
Journal:  Nature       Date:  1990-01-04       Impact factor: 49.962

2.  Successful treatment of chronic idiopathic neutropenia using recombinant granulocyte colony-stimulating factor.

Authors:  T Furukawa; M Takahashi; Y Moriyama; T Koike; I Kurokawa; A Shibata
Journal:  Ann Hematol       Date:  1991-02       Impact factor: 3.673

3.  Multiple spontaneous remissions in a child with acute leukemia. The occurrence of agranulocytosis and aplastic anemia in acute leukemia and their relationship to remissions.

Authors:  F A BASSEN; J L KOHN
Journal:  Blood       Date:  1952-01       Impact factor: 22.113

4.  Anti-thoracic duct lymphocyte globulin stimulates human megakaryocytopoiesis in vitro.

Authors:  K Ogata; K Dan; S Kuriya; T Nomura
Journal:  Blut       Date:  1990-03

5.  Heparan sulphate bound growth factors: a mechanism for stromal cell mediated haemopoiesis.

Authors:  R Roberts; J Gallagher; E Spooncer; T D Allen; F Bloomfield; T M Dexter
Journal:  Nature       Date:  1988-03-24       Impact factor: 49.962

Review 6.  Hypothesis: apoptosis may be the mechanism responsible for the premature intramedullary cell death in the myelodysplastic syndrome.

Authors:  Y Yoshida
Journal:  Leukemia       Date:  1993-01       Impact factor: 11.528

7.  Megakaryocyte, erythroid and granulocyte-macrophage colony formation in myelodysplastic syndromes.

Authors:  K Dan; E An; M Futaki; K Inokuchi; S Gomi; T Yamada; K Ogata; Y Tanabe; I Ohki; T Shinohara
Journal:  Acta Haematol       Date:  1993       Impact factor: 2.195

Review 8.  Spontaneous remission in acute myeloid leukaemia.

Authors:  R Paul; K Remes; T Lakkala; T T Pelliniemi
Journal:  Br J Haematol       Date:  1994-01       Impact factor: 6.998

9.  Granulocyte colony-stimulating factor augments in vitro megakaryocyte colony formation by interleukin-3.

Authors:  I K McNiece; H E McGrath; P J Quesenberry
Journal:  Exp Hematol       Date:  1988-10       Impact factor: 3.084

10.  Marked and reproducible increase in trilineage blood cell counts by administration of granulocyte colony-stimulating factor in a patient with refractory anaemia with excess blasts in transformation.

Authors:  S Chiba; K Inamori; K Mitani; H Hirai; Y Yazaki
Journal:  Br J Haematol       Date:  1994-03       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.